Natera partners with Kupando Therapeutics to use Latitude ctDNA test in Phase 1 skin cancer trial
NTRA•Natera collaboration with Kupando Therapeutics
Natera entered a collaboration with Kupando Therapeutics to support a Phase 1 trial of immunotherapy candidate KUP-101.
- Latitude, Natera’s tissue-free MRD assay, will track serial ctDNA dynamics to monitor treatment response in advanced skin cancers.
- Testing will be conducted at multiple timepoints as patients receive KUP-101 across activated clinical sites, including oncology centers in Germany.
